NCCN Guidelines

Guidelines for Patients

NCCN Guidelines for Patients® are posted with the latest version date.
Acute Lymphoblastic Leukemia (adult)
Version: 2023
Acute Lymphoblastic Leukemia (pediatric)
Version: 2023
Acute Myeloid Leukemia
Version: 2023
Adolescent and Young Adult Cancer
Version: 2023
Adrenal Tumors
Version: 2022
Anal Cancer
Version: 2022
Anemia and Neutropenia - Low Red and White Blood Cell Counts
Version: 2021
Basal Cell Skin Cancer
Version: 2022
B-Cell Lymphomas - Diffuse Large B-Cell Lymphomas
Version: 2024
B-Cell Lymphomas - Follicular Lymphoma
Version: 2022
B-Cell Lymphomas - Mantle Cell Lymphoma
Version: 2023
Bladder Cancer
Version: 2023
Blood Clots and Cancer
Version: 2023
Bone Cancer
Version: 2023
Brain Cancer - Glioma
Version: 2024
Breast Cancer - Ductal Carcinoma In Situ
Version: 2024
Breast Cancer - Inflammatory Breast Cancer
Version: 2023
Breast Cancer - Invasive Breast Cancer
Version: 2024
Breast Cancer - Metastatic Breast Cancer
Version: 2023
Breast Cancer Screening and Diagnosis
Version: 2022
Cervical Cancer
Version: 2024
Chronic Lymphocytic Leukemia
Version: 2024
Chronic Myeloid Leukemia
Version: 2023
Colon Cancer
Version: 2024
Colorectal Cancer Screening
Version: 2021
Distress During Cancer Care
Version: 2024
Esophageal Cancer
Version: 2022
Fatigue and Cancer
Version: 2024
Gallbladder and Bile Duct Cancers
Version: 2023
Gastrointestinal Stromal Tumors (GIST)
Version: 2023
Graft-Versus-Host Disease
Version: 2021
Hodgkin Lymphoma
Version: 2023
Hodgkin Lymphoma in Children
Version: 2023
Immunotherapy Side Effects: CAR T-Cell Therapy
Version: 2024
Immunotherapy Side Effects: Immune Checkpoint Inhibitors
Version: 2022
Kidney Cancer
Version: 2024
Liver Cancer
Version: 2023
Lung Cancer Screening
Version: 2023
Marginal Zone Lymphomas
Version: 2024
Melanoma
Version: 2023
Mesothelioma: Pleural - Malignant Pleural Mesothelioma
Version: 2022
Mouth Cancer
Version: 2024
Multiple Myeloma
Version: 2023
Mycosis Fungoides/Sézary Syndrome
Version: 2021
Myelodysplastic Syndromes
Version: 2021
Myeloproliferative Neoplasms
Version: 2022
Nasopharyngeal Cancer
Version: 2024
Nausea and Vomiting
Version: 2022
Neuroendocrine Tumors
Version: 2022
Non-Small Cell Lung Cancer - Early and Locally Advanced
Version: 2023
Non-Small Cell Lung Cancer - Metastatic
Version: 2023
Ovarian Cancer
Version: 2023
Palliative Care
Version: 2023
Pancreatic Cancer
Version: 2023
Peripheral T-Cell Lymphoma
Version: 2022
Primary Central Nervous System Lymphoma
Version: 2024
Primary Cutaneous Lymphomas
Version: 2021
Prostate Cancer: Advanced Stage
Version: 2023
Prostate Cancer: Early Stage
Version: 2023
Rectal Cancer
Version: 2022
Small Cell Lung Cancer
Version: 2022
Soft Tissue Sarcoma
Version: 2023
Squamous Cell Skin Cancer
Version: 2023
Stomach Cancer
Version: 2023
Survivorship Care for Cancer-Related Late and Long-Term Effects
Version: 2024
Survivorship Care for Healthy Living
Version: 2024
Systemic Mastocytosis
Version: 2022
Throat Cancer
Version: 2024
Thyroid Cancer
Version: 2022
Uterine Cancer
Version: 2023
Waldenström Macroglobulinemia
Version: 2022
The NCCN Guidelines are copyrighted by the NCCN. All rights reserved. NCCN Guidelines and illustrations (including algorithms) may not be reproduced in any form for any purpose without the express written permission of the NCCN. Permissions Requests Section.
3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462
Phone: 215-690-0300
Fax: 215-690-0280
Copyright © National Comprehensive Cancer Network, All Rights Reserved.

No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission.
See Legal Notices Section for additional notices and terms governing your use of this Site.